CD19 CAR-T therapy for relapsed or resistant blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests a treatment called CD19 CAR-T, made from your immune cells, for people whose CD19+ blood cancer has come back or did not respond. It may help your body better recognize and attack cancer cells, but eligibility is tight and the study is still early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed CD19+ B-cell blood cancer: either B-ALL or a type of B-NHL (like DLBCL, FL, or related subtypes).
- Your cancer is “relapsed” or “refractory” (didn’t respond) after prior standard treatment(s), including possible treatment after transplant for some people.
- You have enough cancer activity/visibility for measurement, such as abnormal bone marrow cells for B-ALL or at least one measurable tumor spot for B-NHL.
- Your blood tests and organ function are within limits (liver tests, kidney function, and bilirubin) and you can breathe well (oxygen level at least 92% in room air).
- Your heart function is strong enough (left-heart pumping strength LVEF at least 50%).
- You do not have certain major health exclusions (like pregnancy, uncontrolled infections, HIV, prior CAR-T, or serious brain/heart problems) and you can consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.